Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $100,889 | $106,447 |
| General and administrative | 24,387 | 15,925 |
| Total operating expenses | 125,276 | 122,372 |
| Loss from operations | (125,276) | (122,372) |
| Other income (expense): | ||
| Interest income | 8,757 | 7,100 |
| Interest expense | (4,202) | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s G&A?
- Dyne Therapeutics, Inc. (DYN) reported G&A of $24.39M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s G&A changed year-over-year?
- Dyne Therapeutics, Inc.'s G&A increased by 53.1% year-over-year, from $15.93M to $24.39M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s G&A has grown at a 24.9% compound annual growth rate (CAGR), from $28.72M to $69.85M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Dyne Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude